Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
SINGAPORE, Nov 07, 2018 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) subsidiary Global BioLife Inc. is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California.
SeD said the presentation titled, "Myricetin derivatives ameliorate deficits in 6-OHDA animal model of Parkinson's disease," will detail the results of an Integrated Drug Discovery program at Charles River Discovery Service covering Pharmacokinetics, Maximum Toxicity Dose and an in vivo animal model of Parkinson's Disease. In essence the drug has been designed to work better than current treatments and has performed as well or better in animal models.
"More than 10 million people around the world have Parkinson's Disease," said Dr. Roscoe M. Moore, Jr., former Senior Assistant Surgeon General of the United States and Global BioLife's Chief Scientific Advisor. He also commented that "the team's unique approach to drug development is key to this success."
"We are extremely pleased and hopeful with the initial results of Linebacker and what the data shows for the potential treatment of central nervous system ("CNS") diseases. Linebacker is a direct response to the global need for effective and affordable cures," said Dr. Peihong Tang, Global BioLife's Director and Chief Executive Officer.
"We're excited to have received validating laboratory data of our Linebacker pharmaceuticals," said Mr. Daryl Thompson, Global BioLife's Director of Scientific Initiatives and inventor of the compounds. "This data proves our unique approach to CNS diseases could be a much-needed solution and could ease widespread suffering globally."
With almost 36,000 members, the Society for Neuroscience is the world's largest organisation of scientists and physicians devoted to understanding the brain and the nervous system. Selection for inclusion in this prestigious event is indicative of the compelling results generated by this research.
The abstract for this presentation can be accessed here: https://bit.ly/2yYbA79
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shares are held 20% by Global Research and Discovery Group Scientific LLC, and 10% by ASX-listed Holista CollTech Ltd.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDGS and Holista, GBLI pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with its partners to develop second generation mosquito defense technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com.
This Media Release has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Hong Leong Finance Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this Media Release.
This Media Release has not been examined or approved by SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this Media Release, including the correctness of any of the statements or opinions made or reports contained in this Media Release.
Mr Tang Yeng Yuen, VP, Head of Corporate Finance. Hong Leong Finance Limited, 16 Raffles Quay, 01-05 Hong Leong Blg, Singapore 048581, Tel +65 6415 9886.
Source: Alset International Ltd Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Fujitsu SX Survey reveals key success factors for sustainability Apr 23, 2024 10:25 JST
| Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions Apr 22, 2024 16:09 JST
| NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II Apr 22, 2024 15:09 JST
| Soft Space Launches the First and Only JCB Payment Gateway in Malaysia Apr 22, 2024 15:00 JST
| TOYOTA GAZOO Racing takes a one-two in Croatian thriller Apr 22, 2024 10:47 JST
| First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
| Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan Apr 18, 2024 11:14 JST
| Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Apr 18, 2024 10:53 JST
| All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating Apr 18, 2024 09:22 JST
| Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan Apr 17, 2024 16:17 JST
| Honda Unveils Next-generation EV Series for China Apr 17, 2024 12:15 JST
| Lexus presents Time at the 2024 Milan Design Week Apr 16, 2024 18:49 JST
| Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA Apr 16, 2024 14:36 JST
| New circuit challenge for TOYOTA GAZOO Racing Apr 15, 2024 17:21 JST
| TOYOTA GAZOO Racing back on asphalt for Croatian challenge Apr 12, 2024 19:36 JST
| Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project Apr 12, 2024 14:39 JST
| MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors Apr 11, 2024 18:08 JST
|
More Latest Release >>
|